Subject category:
Strategy and General Management
Published by:
Ivey Publishing
Version: 2009-10-22
Length: 19 pages
Data source: Field research
Share a link:
https://casecent.re/p/14547
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
BLES Biochemicals Inc is a research and development company that specializes in natural surfactants. After many years of trying, the president has finally obtained approval for the company''s only product, BLES. The product is used to help premature babies suffering from respiratory distress syndrome - without it, they could die. The company had been allowed to sell the product in advance of receiving the approval but with the news of receiving the go ahead to use and sell the product, the president had to decide his next move. The obvious step would be to pursue international expansion. The worldwide market potential for BLES was incredible. However, there were trade-offs associated with each of the markets under consideration. Moreover, the inherent risks associated with growth gave him cause for concern. He was anxious to develop a growth strategy that explicitly considered the interests of the company, prospective patients, his family, his partners, and his employees. The supplement BLES Biochemicals Inc (B), ''9B03M027'' follows the events six month later.
About
Abstract
BLES Biochemicals Inc is a research and development company that specializes in natural surfactants. After many years of trying, the president has finally obtained approval for the company''s only product, BLES. The product is used to help premature babies suffering from respiratory distress syndrome - without it, they could die. The company had been allowed to sell the product in advance of receiving the approval but with the news of receiving the go ahead to use and sell the product, the president had to decide his next move. The obvious step would be to pursue international expansion. The worldwide market potential for BLES was incredible. However, there were trade-offs associated with each of the markets under consideration. Moreover, the inherent risks associated with growth gave him cause for concern. He was anxious to develop a growth strategy that explicitly considered the interests of the company, prospective patients, his family, his partners, and his employees. The supplement BLES Biochemicals Inc (B), ''9B03M027'' follows the events six month later.